| abstract |
REFERS TO AMIDE-DERIVED COMPOUNDS OF FORMULA (I) WHERE ARYL IS A 5 OR 6-MEMBER AROMATIC OR HETEROAROMATIC RING; R1 IS CYCLOALKYL (C3-C7), ARYL OR HETEROARYL OPTIONALLY SUBSTITUTED WITH HALOGEN, LOWER ALKYL (C1-C7), LOWER ALCOXY (C1-C7), AMONG OTHERS SUBSTITUTES; R2 IS H O LOWER ALKYL (C1-C7); R3 IS H OR LOWER ALKYL (C1-C7); R4 IS HALOGEN, LOWER ALKYL (C1-C7), LOWER ALCOXY (C1-C7), AMONG OTHERS; R5 IS H, HALOGEN OR LOWER ALKYL (C1-C7) OPTIONALLY REPLACED WITH HALOGEN; X IS A LINK, - (CH2) m-, -CH2O- OR -CH2NH-, WHERE m IS FROM 1 TO 3; n IS 1 O 2; THE DOTTED LINE IS A LINK OR NOT. PREFERRED COMPOUNDS ARE: N - ({[BIS- (3-FLUOR-PHENYL) -MEthyl] -CARBAMOYL} -MEthyl) -4-FLUOR-BENZAMIDE, ({[BIS- (3-FLUOR-PHENYL) -MEthyl] - 5-METHYL-THIOPHENE-2-CARBOXYL ACID CARBAMOYL} -MEthyl) -AMIDE OF 5-METHYL-THIOPHENE-2-CARBOXYL ACID, N - ({[BIS- (3-FLUOR-PHENYL) -MEthyl] -CARBAMOYL} -METHYL) -4-NITRO-BENZAMIDE, BETWEEN OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF GLYCINE TRANSPORTER 1 (GLYT-1) BEING USEFUL IN THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA, DEMENTIA |